王深明
研究领域:血管外科、甲状腺外科、乳腺外科。
个性化签名
- 姓名:王深明
- 目前身份:
- 担任导师情况:
- 学位:
-
学术头衔:
博士生导师
- 职称:-
-
学科领域:
外科学
- 研究兴趣:研究领域:血管外科、甲状腺外科、乳腺外科。
王深明,医学博士、教授、博士生导师,国务院政府特殊津贴专家。现任中山大学附属第一医院(原中山医科大学附属第一医院)院长,血管甲状腺外科首席专家、学科带头人。同时还兼任中华医学会广东外科学会委员,美国外科医师学院院士,国际外科学会委员,亚洲血管外科学会委员,国际内分泌外科学会委员,国际脉管学会委员,亚洲内分泌外科学会委员,国家自然科学基金评审委员,国家科技成果奖评审委员、全国高等院校博士学科点专业科研基金评审委员,中央保健局会诊专家,广东省、广州市保健办会诊专家,广东省医学会常务理事、中国医师协会外科分会副会长、、中国医院协会医疗质量管理专业委员会常委。《中华普通外科文献》(电子版)主编,《中国实用外科杂志》副主编,《岭南现代临床外科》副主编,《中华医学杂志》、《中华普通外科杂志》常务编委、《中华实验外科杂志》、《中国血管外科杂志》、《国际外科杂志》、《中华乳腺病杂志(电子版)》、《中国普外基础与临床杂志》、《现代医院》编委,《中华外科杂志》特约编委等。
研究领域:血管外科、甲状腺外科、乳腺外科。曾获中华医学奖等省、部级以上科技进步、科技成果奖多项,发明专利一项。2003年因在抗击非典工作中表现突出,被广东省委、省政府授予抗击非典三等功,广州市委、市政府授予抗击非典先进个人称号,并被评为全国卫生系统抗击非典先进个人,多次荣获得校、院级优秀党员和先进工作者称号。由于他的学术成就突出, 2007年又荣获广东省第九届丁颖科技奖。近年来主持国家高技术研究发展计划(863计划)2项、国家自然科学基金8项,省部级科研课题8项;在国内外核心期刊上发表论文165篇,其中SCI收录22 篇;主编《血管外科诊断治疗学》、《甲状腺外科学》等专著3部,参编专著20部,参编或主编了2007年全国统编本科教材和研究生教材。
-
主页访问
1721
-
关注数
0
-
成果阅读
797
-
成果数
20
【期刊论文】Arterial Embolization: A Novel Approach to Thyroid Ablative Therapy for Graves' Disease
王深明, HAIPENG XIAO, WENQUAN ZHUANG, SHENMING WANG, BINJIE YU, GUORUI CHEN, MUHENG ZHOU, AND NORMAN C. W. WONG
The Journal of Clinical Endocrinology & Metabolism 87 (8): 3583-3589,-0001,():
-1年11月30日
Despite the availability of effective treatments for Graves' disease, there are patients who are unable to tolerate, or choose not to accept, current therapies (oral medication, radioactive iodine, or surgery). In this study, we have examined the use of thyroid arterial embolization as an option for patients who suffer from Graves' disease and who fit into one of the preceding patient groups. Selective arteriography, followed by embolization of thyroid arteries, was performed using Seldinger's technique in 22 patients with Graves' disease. Six of the patients received both arterial embolization and surgery at 2-3 wk after embolization. No serious complications were noted in any patient. In those who were treated with only interventional embolization, 14 of 22 (63.6%) became euthyroid and remained in this state for the duration of the study. The remaining 2 patients required a maintenance dose of antithyroid drug therapy (tapazole, 5-10 mg/d; or propylthiouracil, 50-100 mg/d). Patients were followed for a median time of 27 months (range, 6-50). At the end of the follow-up period, all 22 patients were euthyroid, the size of thyroid gland had decreased by one third to one half its original volume, but 2 patients continued to require antithyroid drugs. Histologic analysis of thyroid tissue from 6 patients who had embolization followed by surgery showed that embolization blocked both the superior and inferior thyroid arteries plus most of their branches. Evidence of chemical inflammation, necrosis, and fibrosis were observed in embolized thyroid tissue. The average diameter of capillary network within the body of the thyroid adjacent to superior and inferior artery was 0.12-0.25 mm, with the smallest ones ranging from 0.04-0.11 mm. The diameter of the capillaries in the isthmus ranged from 0.13-0.15 mm. The average diameters of the superior and inferior arteries were 2-5.5 and 3-3.75 mm, respectively, measured using radiographs from angiography. Based on the measured diameters of arteries, the appropriate size of embolizing granules can be selected, and complete embolization of the majority of the thyroid glands was achieved with a high frequency of therapeutic success. Histological examination of the thyroid tissue and clinical follow-up after embolization indicate that this procedure is an effective, minimally invasive, and safe method for the treatment of Graves' disease patients who cannot, or choose not to, accept current therapies.
-
33浏览
-
0点赞
-
0收藏
-
0分享
-
75下载
-
0评论
-
引用
【期刊论文】原发性下肢深静脉瓣膜功能不全的大隐静脉曲张致病相关基因的筛选与克隆
王深明, 殷恒讳, 王劲松, 胡作军, 黄雪玲
中华外科杂志,2002,12(12):909~911,-0001,():
-1年11月30日
目的 筛选和克隆原发性下肢深静脉瓣膜功能不全的大隐静脉曲张的致病相关基因。方法 利用mRNA荧光差异显示技术比较原发性下肢深静脉瓣膜功能不全患者的曲张大隐静脉隐-股瓣膜区组织中mRNA表达与对照组的差异,获得的差异表达cDNA片段经Northernblot验证后进行克隆和测序以探明其基因来源。结果 共获得37条差异表达的cDNA条带,经杂交验证其中30条为阳性(阳性率80%)。克隆及测序结果显示C610片段(NO.18克隆)与麦-考综合征(Mckusick-Kaufmansyndrome,MKKS)基因的mRNA序列有96%的同源性。结论 C610片段(NO.18克隆)与麦-考综合征基因高度同源,与下肢大隐静脉曲张的发病密切相关。
静脉曲张; 克隆, 分子; 基因; 病因
-
30浏览
-
0点赞
-
0收藏
-
0分享
-
78下载
-
0评论
-
引用
【期刊论文】sFlt-1 Gene Therapy of Follicular Thyroid Carcinoma
王深明, CAISHENG YE, CHONG FENG, SHENMING WANG, KENT Z. Q. WANG, NANCY HUANG, XIAONING LIU, YONGJIE LIN, AND MENGFENG LI
Endocrinology, February 2004, 145(2): 817-822,-0001,():
-1年11月30日
Tumor progression largely depends on blood supply and neovessel formation, and angiogenesis is emerging as a promising target for cancer therapy. Vascular endothelial growth factor (VEGF), a major proangiogenic molecule, stimulates angiogenesis via promoting endothelial proliferation, urvival and migration. VEGF has been found to be up-regulated in various types of tumors and to be associated with tumor progression and poor prognosis. Inhibition of VEGF or its signaling pathway has been shown to suppress tumor angiogenesis and tumor growth. In the present study, we tested the antiangiogenic and antitumor effects of soluble VEGF receptor-1 [soluble Flt (sFlt)-1] on the growth of follicular thyroid carcinoma (FTC). We constructed a 293 embryonic kidney cell line (293-Flt1-3d) that expresses sFlt-1, which is composed of the first three extracellular domains of Flt-1. The 293-Flt1-3d cells inhibited the in vitro growth of human umbilical vein endothelial cells in a paracrine manner. The in vivo antitumor and antiangiogenic activities of the 293-Flt1-3d cells were tested. When 293-Flt1-3d cells were inoculated at a site remote to the FTC-133 tumor transplant, the growth of FTC-133 tumors were inhibited by 70.37%, as compared with the control treatment with 293 cells expressing control gene LacZ. Immunohistochemical analysis of microvessel densities in treated tumors demonstrated that 293-Flt1-3d cells robustly suppressed intratumoral angiogenesis. Our data suggest that a mammalian cell-mediated approach could effectively deliver sFlt-1 gene therapy and inhibit tumor angiogenesis and tumor growth.
-
75浏览
-
0点赞
-
0收藏
-
0分享
-
56下载
-
0评论
-
引用
【期刊论文】内镜筋膜下交通静脉结扎术治疗重度慢性下肢静脉功能不全51例
王深明, 胡作军, 李晓曦, 吴志棉, 李松奇
中华普通外科杂志,2003,9(9):527~529,-0001,():
-1年11月30日
目的 总结内镜筋膜下交通静脉结扎术(subfascial endoscopic perforator surgery,SEPS)治疗重度慢性下肢静脉功能不全的临床经验。方法 从1999年11月至2002年8月采用SEPS治疗重度慢性下肢静脉功能不全51例,共64条肢体。采用临床分级、静脉功能评分、彩色多普勒超声、彩色多普勒剖面流速图、静脉造影、空气体积描记仪等方法在手术前后对患肢状况进行分析。结果 术后随访率90.6%(58/64),随访3~35个月。全组浅静脉曲张未见复发,有40条肢体溃疡愈合(97.6%),愈合时间平均(32±5)d,手术前后静脉功能综合评分均值分别为(13.9±1.7)分vs.(6.4±0.8)分、手术前后彩超剖面流速图静脉返流量均值分别为(61.2±7.7)ml/svs.(45.6±5.7)ml/s和空气体积描记仪3项指标术前后均值比较均差异有显著意义(P<0.01)。结论 SEPS对于重度慢性下肢静脉功能不全,特别是合并静脉性溃疡者具有良好疗效,如同时行浅静脉缝扎和深静脉瓣膜修复成形可取得更好的疗效。
静脉功能不全, 内窥镜, 血管外科手术
-
42浏览
-
0点赞
-
0收藏
-
0分享
-
81下载
-
0评论
-
引用
-
43浏览
-
0点赞
-
0收藏
-
0分享
-
53下载
-
0评论
-
引用
-
44浏览
-
0点赞
-
0收藏
-
0分享
-
66下载
-
0评论
-
引用
王深明, 常光其, 陈伟, 庄文权, 黄雪玲, 黄灿之, 肖海鹏
中山大学学报(医学科学版),(3S):275~276,-0001,():
-1年11月30日
【目的】总结原发性甲状腺机能亢进症外科治疗的经验。【方法】对100例原发性甲亢病人的外科治疗进行回顾性临床分析。【结果】全部病例均接受双甲状腺次全切除术,术后1例出现呼吸困难需行气管切开,手术治愈率98%。随访4-54个月,平均24.6个月,2例出现甲亢复发,无1例发生甲低。【结论】外科手术是目前治疗原发性甲亢的较佳选择,而正确和充分的术前准备是手术成功的关键。
原发性甲状腺机能亢进, 外科治疗
-
32浏览
-
0点赞
-
0收藏
-
0分享
-
34下载
-
0评论
-
引用
【期刊论文】基因芯片技术筛选原发性下肢深静脉瓣膜功能不全所致大隐静脉曲张的发病相关基因
王深明, 林颖, 殷恒讳
中国实用外科杂志,2004,9(9):554~557,-0001,():
-1年11月30日
目的 利用基因芯片技术分析原发性下肢深静脉瓣膜功能不全(PDVI)所致大隐静脉曲张的基因表达谱和差异基因。方法 对10例PDvI所致的曲张大隐静脉和10例正常对照组织进行mRNA抽提,分别给予荧光素Cy5和Cy3标记以制备cDNA探针,并与含有1220个人类全长互补DNA的基因芯片进行杂交和分析。结果 在PVDI所致的曲张大隐静脉组织中共检测到21个差异基因,其中9个为上调基因,12个为下调基因。差异表达基因包括参与信号传导、细胞周期以及细胞生长、分化、代谢、增殖和凋亡的相关基因。结论 运用基因芯片技术筛选出的差异基因与PvDI所致大隐静脉曲张发病相关。
瓣膜功能不全, 基因芯片, 静脉曲张, 基因表达
-
25浏览
-
0点赞
-
0收藏
-
0分享
-
27下载
-
0评论
-
引用
【期刊论文】用重组表达体系pCKM-mPTH质粒治疗甲状旁腺功能低下症的实验研究
王深明, 朱易凡, 王劲松
中华医学杂志,2004,12(24):2107~2109,-0001,():
-1年11月30日
目的 研究重组pCKM-mPTH质粒在SD大鼠甲状旁腺功能低下症模型中的治疗作用。方法 将30只SD大鼠随机分为3组,A组为正常组,肌肉注射生理盐水,B组、C组制作甲状旁腺功能低下症模型后,分别肌肉注射pcDNA3.1(+)空质粒和pCKM-mPTH质粒。用放免法测定不同时间的血清甲状旁腺激素(PTH)浓度。结果 动物模型在注射pCKM-mPTH质粒后,其血清PTH浓度在近1个月内显著高于注射前及空质粒对照组,未观察到有甲状旁腺功能低下症的表现。结论 应用pCKM-mPTH质粒治疗SD大鼠的甲状旁腺功能低下症是有效的,对未来的临床应用研究有一定的指导意义。
甲状旁腺功能减退症, DNA,, 重组, 基因治疗
-
65浏览
-
0点赞
-
0收藏
-
0分享
-
85下载
-
0评论
-
引用
-
27浏览
-
0点赞
-
0收藏
-
0分享
-
41下载
-
0评论
-
引用